Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: DBT - Phase 2 Clear all
Completed Phase 3 Interventional Results available

Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD

NCT04124614
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Brexpiprazole, Sertraline, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer

NCT00364611
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab, Docetaxel, Trastuzumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 22, 2012 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults

NCT03732638
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
93
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 2, 2026, 4:40 PM EDT
Recruiting Early Phase 1 Interventional

Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

NCT06220214
View directory record Official record
Conditions
Breast Cancer, Locally Advanced Breast Cancer, Neoadjuvant Chemotherapy, HER2-positive Breast Cancer, Triple Negative Breast Cancer, TNBC, Triple Negative Breast Cancer
Interventions
CEDM, CEDBT, Omnipaque 350mgI/mL Solution for Injection
Diagnostic Test · Drug
Lead sponsor
Alison Stopeck
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 2, 2026, 4:40 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)

NCT03801525
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ublituximab, Umbralisib, Venetoclax
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
50
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Not applicable Interventional Results available

CAMPUS - Feasibility Sub-Study

NCT04728815
View directory record Official record
Conditions
Suicide
Interventions
TAU - Phase 1, CAMS - Phase 1, DBT - Phase 1 and 2, CAMS - Phase 2, DBT - Phase 2
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 25 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Reno, Nevada • New Brunswick, New Jersey • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Not applicable Interventional Results available

Developing Adaptive Interventions for Suicidal College Students Seeking Treatment - SMART

NCT02442869
View directory record Official record
Conditions
Suicide
Interventions
Stage 1 Treatment as usual (TAU), Stage 1 CAMS, Stage 2 CAMS, Stage 2 Dialectical Behavioral Therapy (DBT)
Behavioral
Lead sponsor
University of Nevada, Reno
Other
Eligibility
18 Years to 25 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced Sep 2, 2026, 4:40 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

NCT04548999
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Antihistamine, Methylprednisolone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
24
States / cities
Homewood, Alabama • Phoenix, Arizona • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder

NCT04174170
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Brexpiprazole, Sertraline, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 2, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy

NCT04641962
View directory record Official record
Conditions
Primary Mitochondrial Myopathy
Interventions
Bocidelpar, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
La Jolla, California • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 2, 2026, 4:40 PM EDT
Active, not recruiting Phase 3 Interventional

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

NCT04273945
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
43
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 2, 2026, 4:40 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Dialectical Behavioral Therapy in Juvenile Justice

NCT05583279
View directory record Official record
Conditions
Non-Suicidal Self Injury, Suicide, Self-harm, Emotion Regulation
Interventions
Dialetical Behavioral Therapy for Adolescents
Behavioral
Lead sponsor
The Catholic University of America
Other
Eligibility
10 Years to 21 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Not applicable Interventional Results available

Comprehensive Adaptive Multisite Prevention of University Student Suicide

NCT04707066
View directory record Official record
Conditions
Suicide
Interventions
Treatment As Usual (TAU), Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1, Dialectical Behavior Therapy (DBT) - Phase 2, Maintenance/Monitoring - Phase 2, Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 25 Years
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Reno, Nevada • New Brunswick, New Jersey • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

NCT05785624
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
Interventions
Vixarelimab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 2, 2026, 4:40 PM EDT
Recruiting Phase 2 Interventional

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

NCT05941520
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Acolbifene Hydrochloride, Biospecimen Collection, Mammography, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
35 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 2, 2026, 4:40 PM EDT
Active, not recruiting Not applicable Interventional

The Group Risk Reduction Intervention Therapy (GRRIT) Project

NCT05401838
View directory record Official record
Conditions
Suicidal Ideation, Suicide, Attempted, Coping Skills, Depression, Anxiety, PTSD
Interventions
Group Brief Cognitive-Behavioral Therapy (G-BCBT), Dialectical Behavior Therapy (DBT) Skills Group
Behavioral
Lead sponsor
University of North Carolina, Charlotte
Other
Eligibility
18 Years to 99 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 2, 2026, 4:40 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

NCT06335173
View directory record Official record
Conditions
Alzheimer Disease
Interventions
sabirnetug, Placebo
Drug
Lead sponsor
Acumen Pharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Carlsbad, California • Fullerton, California • Irvine, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 2, 2026, 4:40 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

NCT04544436
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Antihistamine, Methylprednisolone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
25
States / cities
Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 2, 2026, 4:40 PM EDT